Baotou, China

Furong Wang

This inventor holds 1 USPTO granted patent. Top assignees: Baotou Dongbao Bio Tech Co Ltd., Chinese Academy of Sciences, Other. Active years: 2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Furong Wang. Retrieved from https://idiyas.com/inventor/furong-wang-z3doghp0

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Furong Wang: Inventor of Collagen Active Peptide Technology

Introduction

Furong Wang is an inventor associated with Baotou, China. Her work includes a patented method for preparing collagen active peptides with antiproliferative activity against cancer cells.

Latest Patents

Wang is credited with 1 patent, titled “Techniques of Preparing Collagen Active Peptides.” The invention describes producing collagen active peptides through hydrolysis using papain and trypsin, followed by a specific purification process. The resulting peptides are reported to have antiproliferative activity against ovarian carcinoma cell lines, including SKOV3, OVCAR3, 436, and SRO82, as well as prostate cancer cell lines PC3, LnCAPC1, and LnCAPC2.

Career Highlights

Wang’s professional affiliations include the Chinese Academy of Sciences and Baotou Dongbao Bio Tech Co., Ltd. Her patent work connects biotechnology research with the preparation of bioactive peptides.

Collaborations

Wang’s listed coworkers include Yanchuan Guo and Eric Hanxiang Sun.

Conclusion

Furong Wang’s patent focuses on a defined process for preparing collagen active peptides and reports their antiproliferative activity against selected cancer cell lines.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…